In a 2023 study, pretreatment mutations, deletions, fusions, and amplifications of 83 cancer-associated genes were evaluated in the ctDNA of 44 patients with PSMA-positive mCRPC prior to therapy with PSMA-targeted RLT ([177Lu]Lu-PSMA-I&T and [177Lu]Lu-PSMA-617) (37). Here, FOLH1 is linked to cancer.